Grégoire Murielle, Tadié Jean-Marc, Uhel Fabrice, Gacouin Arnaud, Piau Caroline, Bone Nathaniel, Le Tulzo Yves, Abraham Edward, Tarte Karin, Zmijewski Jaroslaw W
Unité Mixte de Recherche (UMR) U917, INSERM, Rennes, France.
UMR U917, Université Rennes 1, Rennes, France.
J Leukoc Biol. 2017 Jun;101(6):1281-1287. doi: 10.1189/jlb.5HI0316-128RR. Epub 2016 Dec 13.
Sepsis is accompanied by the initial activation of proinflammatory pathways and long-lasting immunosuppression that appears to contribute to late-occurring mortality. Although high-mobility group box 1 (HMGB1) is involved in many aspects of inflammation, its role in sepsis-induced immune suppression remains unclear. In this study, we examined HMGB1's contribution to neutrophil NADPH oxidase activity dysfunction and associated neutrophil-dependent bacterial clearance in mice subjected to sepsis and in patients who survive septic shock. Using a murine model of polymicrobial septic peritonitis, we demonstrated that treatment with anti-HMGB1 Ab significantly diminished sepsis-induced dysfunction of neutrophil NADPH oxidase activity. In a subsequent set of experiments, we found that blocking HMGB1 preserved the ability of neutrophils from patients recovering from septic shock to activate NADPH oxidase. Taken together, our data suggest that HMGB1 accumulation in the late phase of sepsis plays a specific role in the development of postsepsis immunosuppression and specifically affects neutrophil-dependent antibacterial defense mechanisms. Thus, blocking HMGB1 may be a promising therapeutic intervention to diminish the adverse effects of sepsis-induced immunosuppression.
脓毒症伴有促炎途径的初始激活和持久的免疫抑制,而后者似乎导致了后期的死亡。尽管高迁移率族蛋白B1(HMGB1)参与炎症的许多方面,但其在脓毒症诱导的免疫抑制中的作用仍不清楚。在本研究中,我们研究了HMGB1对脓毒症小鼠和感染性休克存活患者中性粒细胞NADPH氧化酶活性功能障碍及相关的中性粒细胞依赖性细菌清除的影响。使用多微生物性脓毒症腹膜炎小鼠模型,我们证明用抗HMGB1抗体治疗可显著减轻脓毒症诱导的中性粒细胞NADPH氧化酶活性功能障碍。在随后的一系列实验中,我们发现阻断HMGB1可保留感染性休克恢复患者中性粒细胞激活NADPH氧化酶的能力。综上所述,我们的数据表明,脓毒症后期HMGB1的积累在脓毒症后免疫抑制的发展中起特定作用,并特别影响中性粒细胞依赖性抗菌防御机制。因此,阻断HMGB1可能是一种有前景的治疗干预措施,以减轻脓毒症诱导的免疫抑制的不良影响。